Clinical trials: Hematologic Neoplasm
- Condition Hematologic Neoplasm
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory
Cancer, Solid Tumor Cancer
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.
- Conditions
- Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies
- Trial name
- ONCO-OLIVIA (NCT07756034)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tempus AI
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hematological Malignancy
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
- Trial name
- NCT06586671
- Testing
- Nemtabrutinib
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancy, Solid Tumor
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers
- Conditions
- Hematologic Malignancy, Solid Tumor, Fibrosis
- Trial name
- NCT05716919
- Testing
- Ivaltinostat
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Machaon Biotherapeutics, Inc.
Oncology, Hematologic Malignancy
AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)
Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations.
- Conditions
- Oncology, Hematologic Malignancy, Gastro-Intestinal Disorder, Autoimmune Diseases
- Trial name
- NCT05889806
- Testing
- Observational Study Only. NO Intervention.
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Audubon Bioscience
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research Uses
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT03848962
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT05080907
- Testing
- Observational
- Where
- 7 sites in United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Cancer, Solid Tumor
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.
- Conditions
- Cancer, Solid Tumor, Hematologic Neoplasms
- Trial name
- NCT04264767
- Testing
- Blood collection
- Where
- 3 sites in United States, Israel
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Nucleix Ltd.
Solid and Hematological Malignancies
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
This is a two-part, open-label, randomized, crossover study in healthy subjects (vasectomized males and women of non-childbearing potential), performed at 2 study centers
- Trial name
- NCT04944771
- Testing
- Capivasertib, Rabeprazole
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Neoplasms, Non-hematologic - Stage I-III
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing…
- Trial name
- NCT03071809
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Lexent Bio, Inc.